Novartis: Osteoarthritis trials
The registry lists 26 Osteoarthritis studies with Novartis as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 3Phase 2 8Phase 3 13Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Proof-of-concept Study to Examine QUC398 in Participants With Knee OATerminatedNCT05462990Phase 2Results posted
- Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee OsteoarthritisCompletedNCT04886258Phase 2Results posted
- Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee OsteoarthritisTerminatedNCT04864392Phase 2Results posted
- A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)TerminatedNCT04814368Phase 2Results posted
- Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OACompletedNCT04097379Phase 2Results posted
- Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.CompletedNCT03275064Phase 2Results posted
- To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the KneeCompletedNCT01160822Phase 2Results posted
- Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis ParticipantsCompletedNCT04564053Phase 1
- First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee ReplacementCompletedNCT02491281Phase 1
- Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)CompletedNCT00959439Phase 1
- Safety of Lumiracoxib in Patients With OsteoarthritisCompletedNCT00637949Phase 3
- Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)CompletedNCT00476034Phase 3
- Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)CompletedNCT00475800Phase 3
- Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled HypertensionCompletedNCT00419796Phase 4
- Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the KneeCompletedNCT00371670Phase 2
- Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)CompletedNCT00367315Phase 3
- Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).CompletedNCT00366938Phase 3
- Efficacy and Safety of LumiracoxibCompletedNCT00267215Phase 3
- Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled HypertensionCompletedNCT00267176Phase 4
- Safety of Diclofenac Sodium Gel in Knee OsteoarthritisCompletedNCT00171691Phase 3
- Efficacy and Safety of Diclofenac Sodium Gel in Hand OsteoarthritisCompletedNCT00171665Phase 3
- Efficacy and Safety of Diclofenac Sodium Gel in Hand OsteoarthritisCompletedNCT00171652Phase 3
- Efficacy and Safety of Diclofenac Sodium Gel in Knee OsteoarthritisCompletedNCT00171626Phase 3
- 6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid ArthritisCompletedNCT00170872Phase 3
- Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip OsteoarthritisCompletedNCT00154219Phase 3
- 52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or SpineCompletedNCT00145301Phase 3